Cell therapy partnership between Bay Area biotechs offers hope to cancer patients

Imagine a world in which physicians can confidently cure cancer. Two Bay Area life sciences companies are working together to make this vision a reality. Atara Biotherapeutics Inc., founded in 2012, is developing a pipeline of cell therapies to treat various types of cancer and autoimmune diseases. Bayer is licensing Atara’s cutting-edge cell therapies that t arget certain types of aggressive tumors including mesothelioma, pancreatic, ovarian and non-small-cell lung cancer. “With cancer therapies,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

AbstractActive hexose-correlated compound (AHCC) is a standardized extract from culturedLentinula edodes mycelia, used as a potent biological response modifier in cancer treatment. We evaluated the nutritional effect of AHCC, given during neoadjuvant therapy, to patients with pancreatic ductal adenocarcinoma (PDAC). Thirty patients with resectable or borderline-resectable PDAC received neoadjuvant therapy with gemcitabine plus S-1. We compared, retrospectively, the outcomes of 15 patients who received AHCC combined with neoadjuvant therapy with those of 15 patients who did not receive AHCC combined with neoadjuvant therapy...
Source: Surgery Today - Category: Surgery Source Type: research
AbstractPurposeRadical antegrade modular pancreatosplenectomy (RAMPS) has been reported to achieve high rates of a negative margin and resected metastatic lymph nodes. However, many studies have used historical controls and the results remain controversial. We conducted this study to compare the surgical and long-term outcomes of RAMPS vs. conventional distal pancreatectomy (DP).MethodsThe subjects of this multicenter retrospective study were 106 patients who underwent curative resection for left-sided pancreatic cancer between 2012 and 2017. Overall survival (OS) and recurrence-free survival (RFS) rates were compared usin...
Source: Surgery Today - Category: Surgery Source Type: research
AbstractPurposeTo assess the clinical indications for, and prognostic impact of surgery after, chemotherapy for type 4 gastric cancer.MethodsThe subjects of this retrospective study were 67 patients who received chemotherapy for type 4 gastric cancer. The patients were grouped into those with progressive disease (PD group) and those without PD (non-PD group), according to the tumor response to chemotherapy.ResultsDistant metastases developed in 58 patients. With regard to tumor response, there were 16 patients in the PD group and 51 patients in the non-PD group. The prognosis of the PD group patients was significantly poor...
Source: Surgery Today - Category: Surgery Source Type: research
AbstractAdvanced gastric cancers are responsible for overwhelming human suffering and death. Despite the development of combination chemotherapies, the survival rates of patients with gastric cancer remain unsatisfactory. Given the growing evidence of the benefits of immunotherapy as an alternative treatment for other cancers such as advanced melanoma, non-small cell lung cancer, renal cell carcinoma, and refractory Hodgkin ’s lymphoma, researchers have begun to explore its application in the treatment of gastric cancer. Three types of immunotherapy have shown promising effects against gastric cancer: immune checkpoi...
Source: Surgery Today - Category: Surgery Source Type: research
This study aimed to identify the risk factors associated with performing a difficult laparoscopic radical resection of rectal cancer, and to establish a predictive nomogram to help individual clinical treatment decisions.MethodsA total of 977 patients with rectal cancer who underwent laparoscopic radical resection between January 2014 and December 2016 were enrolled in this study. The difficulty of laparoscopic-assisted rectal resection (LARR) was defined according to the scoring criteria reported by Escal. A logistic regression analysis was performed to identify the variables that may affect the difficulty of LARR, and a ...
Source: Surgery Today - Category: Surgery Source Type: research
AbstractPalliative chemotherapy with best supportive care is a mainstay for patients with gastric cancer (GC) and distant metastasis. However, with advances in GC chemotherapy, multimodal treatment, including perioperative chemotherapy plus conversion surgery, has attracted attention as a new strategy to improve the outcome of patients with stage IV disease. Conversion surgery is defined as surgical treatment aimed at R0 resection after a good response to induction chemotherapy for tumors originally considered unresectable or marginally resectable for technical and/or oncological reasons. Various biological characteristics...
Source: Surgery Today - Category: Surgery Source Type: research
Progestogens are steroid compounds that have the ability to induce secretory transformation in the endometrium and are utilized in menopausal hormone therapy to prevent endometrial hyperplasia and endometrial cancer. Progestogens can be derived from 21-carbon or 19-carbon steroid cytoskeletons and thus have different properties and metabolic effects beyond the progestational effects on the endometrium. This limited review will focus on the available progestogens utilized in combination hormone therapy including progesterone, medroxyprogesterone acetate, norethindrone, norethindrone acetate, levonorgestrel, and drospirenone...
Source: Clinical Obstetrics and Gynecology - Category: OBGYN Tags: Hormone Use in Gynecology Source Type: research
Selective estrogen receptor (ER) modulators have variable tissue specific estrogen agonist and antagonist activities. Tamoxifen is approved for treatment and prevention of breast cancer; acts as an endometrial estrogen agonist. Raloxifene is approved for prevention and treatment of osteoporosis and prevention of breast cancer. The selective ER modulators bazedoxifene paired with conjugated estrogens relieves vasomotor symptoms and prevents bone loss with neutral effects on breast and amenorrhea similar to placebo. Ospemifene is approved to treat dyspareunia. Lasofoxifene is in development for resistant ER positive breast c...
Source: Clinical Obstetrics and Gynecology - Category: OBGYN Tags: Hormone Use in Gynecology Source Type: research
We described a patient who developed four limb distal paraesthesia, postural instability, and facial  diplegia, ten days after vaccination with ChAdOx1 nCoV-19 (ABW1277). The electrophysiological findings were compatible with acute demyelinating motor polyneuropathy (Guillain-Barrè syndrome).DiscussionWe therefore want to describe a temporal correlation between administration of ChAdOx1 nCoV-19  (ABW1277) vaccine and GBS without evidence of other predisposing infectious or autoimmune factors. This paper aims to highlight the importance of pharmacovigilance and subsequent reports will be needed&nb...
Source: Neurological Sciences - Category: Neurology Source Type: research
Source: Neurological Sciences - Category: Neurology Source Type: research
More News: Asbestosis | Autoimmune Disease | Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Health Management | Legislation | Lung Cancer | Mesothelioma | Non-Small Cell Lung Cancer | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Partnerships | Pharmaceuticals